Pfizer Inc., flush with cash from its COVID-19 vaccine, will buy the clinical-stage immuno-oncology company Trillium Therapeutics Inc. for $2.26bn in an acquisition that will bolster Pfizer's hematology pipeline with two clinical stage compounds targeting a new immune checkpoint, the firms announced 23 August. The acquisition is in line with Pfizer's stated M&A strategy of bringing in mid-stage assets that could drive revenue growth in the 2025-2030 timeframe.
The two lead assets – TTI-622 and TTI-621 – target signal-regulatory protein α (SIRPα -CD47), considered a key immune checkpoint...








